Medtronic today announced that it received FDA expanded approval for its Freezor and Freezor Xtra cardiac cryoablation catheters for pediatric atrioventricular nodal reentrant tachycardia (AVRNT).
AVNRT is the most common form of supraventricular tachycardia and involves a life-threatening abnormal heart rhythm. More than a third of AVRNY cases are in pediatrics or children under the age of 18, Medtronic reports. The heart disorder can cause a very rapid heart rhythm and, if left untreated, can affect the heart’s ability to pump normally.
Medtronic designed the Freezor and Freezor Xtra catheters as flexible, single-use devices that freeze cardiac tissue and block unnecessary electrical signals in the heart. The focal cryoablation therapy has treated more than 140,000 patients across 67 countries, according to the company.
Get the full story on our sister site, Medical Tubing + Extrusion.